Gilead Sciences presented a strategy centered on HIV prevention growth at the UBS Global Biopharma Conference on November 17, 2026. Chief Financial Officer Andy Dickinson said the company is entering a new growth phase with no major patent expirations through 2036.
Gilead's HIV prevention injection Yeztugo is now expected to generate $1 billion in 2026 sales, surpassing the company's earlier target of about $800 million. The HIV prevention franchise reached $4 billion in annual revenue. Dickinson said roughly 66% to 75% of Yeztugo users are switching from daily oral therapies, while a meaningful share are new to prevention treatment entirely.
The company plans to expand the Yeztugo franchise with a weekly oral version expected in early 2027 and a yearly injection in 2028. Dickinson noted that about 70% of the HIV prevention market does not want an injectable product, making the oral version a potentially larger opportunity than the current long-acting shot.
Gilead expects base business growth of 10% to 11% in 2026, excluding VEKLURY, its COVID drug. VEKLURY sales have fallen to about $300 million from a peak of $5.6 billion five years ago. Biktarvy, Gilead's leading HIV treatment pill, grew 10% year over year in the third quarter of 2026. The company said it still expects a $1.5 billion headwind in 2028 from drug-price negotiation on Biktarvy.
Anito-cel, Gilead's BCMA CAR-T therapy for multiple myeloma, is set for a December 23, 2026 PDUFA date. Dickinson said the drug's safety profile could compare favorably with CARVYKTI, noting anito-cel does not appear to carry the long-term neurological toxicities seen in competitor labels.
Gilead also highlighted a growing immunology pipeline, including emvistegrast and an IRAK4 program in lupus.
Investors tracking GILD should monitor the December 2026 anito-cel decision and the February 2027 PDUFA date for the weekly oral Yeztugo formulation.